Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Dexfosfoserine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.57 |
| ▸ | PGK2 | P07205 | 1/20 | 0.57 |
| ▸ | PGD | P52209 | 2/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.42 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexfosfoserine SCHEMBL4285884 | 1.00 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL6846 | 0.98 | PGK1 (0.59) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL6847 | 0.98 | PGK1 (0.59) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL29427835 | 0.98 | PGK1 (0.59) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL20798048 | 0.98 | PGK1 (0.59) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL10496255 | 0.96 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL5654871 | 0.96 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL28140769 | 0.96 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL28108476 | 0.96 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 | |
| Dexfosfoserine SCHEMBL27820998 | 0.96 | PGK1 (0.57) | PGK1PGK2PGDS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947960-A | Ultrasonic response type intracellular protonizing and editing tool, and preparation method and application thereof | 复旦大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-106459857-B | Ammonia control device and ammonia control method | 味之素株式会社 | 2019-04-19 | — | — | CN | disclosed |
| CN-106459857-A | Ammonia control device and ammonia control method | 味之素株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-20120295802-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 | NATIONAL INSTITUTES OF HEALTH | 2012-11-22 | — | — | US | disclosed |
| US-20090143997-A1 | Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1 | NATIONAL INSTITUTES OF HEALTH | 2009-06-04 | — | — | US | disclosed |
| EP-1773389-A4 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 | MASSACHUSETTS INST TECHNOLOGY (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1773389-A2 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 | Massachussets Institute of Technology (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060052951-A1 | Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1 | NATIONAL INSTITUTES OF HEALTH | 2006-03-09 | — | — | US | disclosed |
| WO-2005115454-A2 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-12-08 | — | — | WO | disclosed |
| CN-1596267-A | Genes coding for regulatory proteins | BASF AG (DE) | 2005-03-16 | — | — | CN | disclosed |
| US-6395528-B1 | Phosphoserine phosphatase gene of coryneform bacteria | AJINOMOTO CO., INC. (JP) | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295802-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1 | BACH1, BRCA1, BRAP | PGK1 1515/4885PGK2 1964/4885PGD 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.